Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Takeshi Iwaya"'
Autor:
Hidekazu Shirota, Keigo Komine, Masanobu Takahashi, Shin Takahashi, Eisaku Miyauchi, Hidetaka Niizuma, Hiroshi Tada, Muneaki Shimada, Tetsuya Niihori, Yoko Aoki, Ikuko Sugiyama, Maako Kawamura, Jun Yasuda, Shuhei Suzuki, Takeshi Iwaya, Motonobu Saito, Tsuyoshi Saito, Hiroyuki Shibata, Toru Furukawa, Chikashi Ishioka
Publikováno v:
Cancer Medicine. 12:6170-6181
A paradigm shift has occurred in cancer chemotherapy from tumor-specific treatment with cytotoxic agents to personalized medicine with molecular-targeted drugs. Thus, it is essential to identify genomic alterations and molecular features to recommend
Autor:
Tomoko Takahashi, Takeshi Iwaya, Takashi Tokino, Satoshi Nishizuka, Yuji Akiyama, Tomomi Hirano, Masashi Idogawa, Yasushi Sasaki, Masakazu Abe, Fumitaka Endo, Akira Sasaki, Hayato Hiraki, Yuka Koizumi, Noriyuki Sasaki, Fumiaki Takahashi, Ryosuke Fujisawa, Shoichiro Tange, Mari Masuda, Mizunori Yaegashi
Publikováno v:
Carcinogenesis. 42:1239-1249
PurposeWe investigated whether early circulating tumor DNA (ctDNA) changes, measured using digital PCR (dPCR), can predict later chemotherapy responses in esophageal squamous cell cancer (ESCC).DesignWe compared the dynamics of ctDNA and tumor volume
Publikováno v:
Cancer Research. 83:6704-6704
Background: Circulating tumor DNA (ctDNA), a new class of tumor marker, has been demonstrated the clinical validity of: 1) early relapse prediction, 2) therapeutic efficacy evaluation, and 3) relapse-free corroboration in the context of cancer treatm
Publikováno v:
Cancer Research. 83:5599-5599
Background: Many patients undergo a next generation sequencing (NGS)-based cancer genome profiling (CGP) test, but it often does not aid in choosing an optimal therapeutic regimen. Therefore, the genomic information should be used for minimal residua
Autor:
Doris R. Siwak, Toshimoto Kimura, Kei Sato, Hidewaki Nakagawa, Takeshi Iwaya, Masashi Fujita, Noriyuki Sasaki, Lance A. Liotta, Satoshi Nishizuka, Fumitaka Endo, Yiling Lu, Tsuyoshi Hachiya, Mizunori Yaegashi, Koki Otsuka, Tamotsu Sugai, Gordon B. Mills, Ryo Sugimoto, Zhenlin Ju
Publikováno v:
British Journal of Cancer
Background Circulating tumour DNA (ctDNA) is known as a tumour-specific personalised biomarker, but the mutation-selection criteria from heterogeneous tumours remain a challenge. Methods We conducted multiregional sequencing of 42 specimens from 14 c
Autor:
Ryunosuke Kogo, Tomomi Manako, Takeshi Iwaya, Satoshi Nishizuka, Hayato Hiraki, Yasushi Sasaki, Masashi Idogawa, Takashi Tokino, Ayaka Koide, Noritaka Komune, Ryuji Yasumatsu, Takashi Nakagawa
Publikováno v:
Cancer medicine. 11(21)
There is no useful biomarker to evaluate treatment response and early relapse in head and neck squamous cell carcinoma (HNSCC). Circulating tumor DNA (ctDNA) is a promising biomarker for detecting minimal residual diseases and monitoring treatment ef
Autor:
Yuka, Koizumi, Sheny, Ahmad, Miyuki, Ikeda, Akiko, Yashima-Abo, Ginny, Espina, Ryo, Sugimoto, Tamotsu, Sugai, Takeshi, Iwaya, Gen, Tamura, Keisuke, Koeda, Lance A, Liotta, Fumiaki, Takahashi, Satoshi S, Nishizuka
Publikováno v:
J Natl Cancer Inst
Background Paradoxically, Helicobacter pylori–positive (HP+) advanced gastric cancer patients have a better prognosis than those who are HP–negative (HP-). Immunologic and statistical analyses can be used to verify whether systemic mechanisms mod
Autor:
Doris R. Siwak, Hidewaki Nakagawa, Takehiro Chiba, Lance A. Liotta, Zhenlin Ju, Mizunori Yaegashi, Tsuyoshi Hachiya, Takeshi Iwaya, Gordon B. Mills, Masashi Fujita, Yiling Lu, Noriyuki Sasaki, Tamotsu Sugai, Satoshi Nishizuka, Ryo Sugimoto, Fumitaka Endo
Publikováno v:
PLoS ONE, Vol 15, Iss 10, p e0239966 (2020)
PLoS ONE
PLoS ONE
Circulating tumor DNA (ctDNA) is released from tumor cells into blood in advanced cancer patients. Although gene mutations in individual tumors can be diverse and heterogenous, ctDNA has the potential to provide comprehensive biomarker information. H
Autor:
Takashi Kobunai, Kohei Kume, Takeshi Iwaya, Mamoru Nukatsuka, Akari Konta, Kaoru Ishida, Kei Sato, Teiji Takechi, Chie Ito, Yukimi Ohmori, Yuka Koizumi, Satoshi Nishizuka
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-13 (2017)
Scientific Reports
Scientific Reports
Drug-tolerant cancer cell subpopulations are responsible for relapse after chemotherapy. By continuously exposing the gastric cancer cell line MKN45 to 5-FU for >100 passages, we established a 5-fluorouracil (5-FU)-tolerant line, MKN45/5FU. Orthotopi
Autor:
Satoshi Nishizuka, Takashi Tokino, Fumiaki Takahashi, Fumitaka Endo, Takeshi Iwaya, Yasushi Sasaki
Publikováno v:
Gastroenterology. 160:463-465.e4